Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) were the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 20,716,430 shares, a growth of 9.8% from the March 31st total of 18,875,693 shares,AnalystRatingsNetwork reports. Based on an average daily volume of 1,554,211 shares, the days-to-cover ratio is presently 13.3 days. Currently, 35.4% of the shares of the company are short sold. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), shares after opening at $3.58 moved to $3.70 on last trade day and at the end of the day closed at $3.58. Company price to sales ratio in past twelve months was calculated as 450.05 and price to cash ratio as 5.28. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), showed a positive weekly performance of 0.85%.
On May 01, 2014, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced that it will report financial results for the first quarter ending March 31, 2014 on Thursday, May 8, 2014, after the U.S. financial markets close. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), shares advanced 9.89% in last trading session and ended the day on $54.34. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), return on equity ratio is recorded as -30.10% and its return on assets is -19.80%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), yearly performance is 138.52%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), gained 10.58% after the company announced that HETLIOZ(TM) is now available. This is the 1st treatment that has been approved by the Food & Drug Administration for Non-24-Hour-Sleep-Wake Disorder. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), shares moved up 5.46% in last trading session and was closed at $14.69, while trading in range of $ 13.33 – 14.76. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), year to date (YTD) performance is 18.37%.
On May 01, 2014, EXACT Sciences Corporation (NASDAQ:EXAS), announced its financial results for the quarter March 31, 2014. EXACT Sciences Corporation (NASDAQ:EXAS), weekly performance is -4.12%. On last trading day company shares ended up $12.56. EXACT Sciences Corporation (NASDAQ:EXAS), distance from 50-day simple moving average (SMA50) is -6.28%. Analysts mean target Price for the company is $18.82.